Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Approved
Recipient : Lipocine
Deal Size : Undisclosed
Deal Type : Agreement
Lipocine And Pharmalink to Commercialize TLANDO® in GCC Countries
Details : Pharmalink will have the exclusive rights to Tlando, an oral testosterone replacement therapy indicated for deficiency or absence of endogenous testosterone, throughout the GCC region.
Brand Name : Tlando
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 08, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Recipient : Lipocine
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
